中文摘要：

目的 探讨血清HCV核心蛋白与抗病毒治疗效果的相关性.方法 采用ELISA法检测162例丙型肝炎患者血清HCV核心蛋白量,采用荧光定量PCR检测HCV RNA;观察35例接受聚乙二醇干扰素＋利巴韦林治疗的患者在治疗前、治疗4周、治疗24周、治疗48周时HCV RNA与HCV核心蛋白水平,比较两者血清水平随临床疗效变化的一致性.两组计量资料比较采用t检验,多组配对资料进行方差分析.结果 162例患者中56例HCV RNA≤1×103IU/mL,HCV核心蛋白吸光度（A）值为0.100±0.029;9例1×103IU/mL＜HCV RNA≤1×104 IU/mL,A值为0.246±0.213;11例1×104IU/mL＜HCV RNA≤1×105IU/mL,A值为0.235±0.179;28例1×105 IU/mL＜HCV RNA≤1×106IU/mL,A值为0.422±0.319;51例1×106IU/mL＜HCVRNA≤1×107IU/mL,A值为0.603±0.330;7例1×107IU/mL＜HCV RNA≤1×108IU/mL,A值为0.900±0.379.对HCV RNA与HCV核心蛋白水平进行相关性分析,结果呈正相关（r=0.36,P＜0.05）.35例接受抗病毒治疗患者治疗前、治疗4周、治疗24周和治疗48周时的核心蛋白A值分别为0.564±0.296、0.144±0.062、0.091±0.035和0.112±0.103.与抗病毒治疗前比较,治疗4周、24周、48周患者血清HCV核心蛋白水平均明显下降（t=8.563、9.195、9.250,均P＜0.05）;治疗4周与24周比较,差异也有统计学意义（t=4.301,P＜0.05）.结论 在疾病进程及抗病毒治疗过程中血清HCV核心蛋白的量的变化与HCV病毒载量变化是平行的.

英文摘要：

Objective To evaluate the relationship between serum level of hepatitis C virus （HCV） core protein and antiviral therapy response in patients with hepatitis C. MethodsOne hundred and sixty-two consecutive patients with chronic hepatitis C （CHC） were retrospectively analyzed. Serum level of HCV core protein and HCV RNA were measured. Among them, 35 CHC patients treated with pegylated interferon （PEG-IFN）＋ ribavirin （RBV） were followed up before and at week 4, 24, 48 of treatment. The correlations between serum HCV core protein level, HCV RNA and antiviral therapy were evaluated. Comparison between groups was done by t test and comparison of paired data among groups was done by analysis of variance. Results Total 162 patients were divided into six groups according to the HCV virus load： 56 with HCV virus load≤1×103 IU/mL and HCV core protein absorbance （A）=0. 100±0. 029; 9 with 1×103 IU/mL〈 HCV virus load≤1 × 104 IU/mLand A=0. 246±0. 213; 11 with 1 × 104 IU/mL〈 HCV virus load≤1 × 105 IU/mL and A=0. 235±0.179; 28 with 1×105 IU/mL〈 HCVvirusload≤1×106 IU/mL and A=0. 422±0. 319; 51 with 1 × 106 IU/mL〈 HCV virus load≤ 1 × 107 IU/mL and A = 0. 603 ± 0. 330 ; 7 with 1 × 107 IU/mL〈HCV virus load≤ 1 × 108 IU/mL and A = 0. 900± 0. 379. The HCV core protein absorbance was positively correlated with HCV RNA level （r= 0.36, P〈0.05）. The HCV core protein absorbance values of 35 CHC patients before therapy, at week 4, 24, and 48 of therapy were 0. 564 ±0. 296,0. 144±0. 062, 0. 091 ±0. 035 and 0. 112±0. 103, respectively. The HCV core protein absorbance values at week 4, 24, 48 all decreased significantly compared with that before therapy （t= 8. 563,9. 195, 9. 250; all P〈0.05）, and there was significant difference between those at week 4 and week 24 （t=4. 301, P〈0.05）. Conclusion Serum HCV core protein level is closely correlated with HCV viral load during HCV infection process and antiviral treatment.